Background. Binding of the steroidal molecule of rocuronium by a cyclodextrin is a new concept for reversal of neuromuscular block. The present study evaluated the ability of Sugammadex Org 25969, a synthetic g-cyclodextrin derivative, to reverse constant neuromuscular block of about 90% induced by rocuronium or the non-steroidal neuromuscular blocking drugs, mivacurium or atracurium, in the anaesthetized Rhesus monkey.
This new method lacks the well-known side-effects associated with the use of cholinesterase inhibitors, as cyclodextrin derivatives do not interfere with other molecules or receptor systems, in particular the muscarinic system. 1 Sugammadex (Org 25969) is a synthetic derivative of g-cyclodextrin designed to selectively bind the steroidal neuromuscular blocking drug rocuronium. Binding of the rocuronium molecule results in a rapid decrease in rocuronium concentration in plasma and subsequently at the motor endplate, which in turn results in reappearance of muscle activity. 1 3 4 Calorimetry and X-ray crystallography have confirmed that sugammadex forms a complex with rocuronium, binding the rocuronium molecule within the cyclodextrin ring. reverse neuromuscular block induced by steroidal neuromuscular blocking agents in an in vitro mouse hemidiaphragm preparation and in vivo in cat, guinea pig and Rhesus monkey experiments and finally in human volunteers. 1 3-8 Currently, limited data are available to demonstrate the reversibility of neuromuscular block induced by non-steroidal neuromuscular blocking agents by sugammadex. 5 7 The first part of the present study evaluated the action of sugammadex at doses of 0.5 and 1.0 mg kg À1 in reversing constant 90% neuromuscular block, induced by continuous rocuronium infusion in the anaesthetized Rhesus monkey, using train-of-four (TOF) stimulation. The second part of this study used the same methods to evaluate the action of sugammadex at a dose of 1.0 mg kg À1 in reversing constant 90% neuromuscular block induced by continuous infusion of two non-steroidal neuromuscular blocking agents, mivacurium or atracurium.
Methods
These in vivo experiments were performed in the experimental laboratories of the Department of Anaesthesiology at the University Medical Centre in Nijmegen, The Netherlands. The experiments were approved by the regional ethical committee on animal experiments.
Female Rhesus monkeys (CSIMS, Beijing, China) were sedated with ketamine 10 mg kg À1 (Nimatek Eurovet) administered by i.m. injection. Two i.v. lines were inserted; one for anaesthetic administration, including rocuronium, the other for test drug administration. Anaesthesia was induced by i.v. bolus injection of pentobarbital sodium (Ceva Sante Animale, 25 mg kg
À1
) and a subsequent continuous infusion of 5-10 mg kg À1 h À1 . The monkeys were intubated endotracheally and the lungs ventilated with a mixture of oxygen and nitrous oxide at a ratio of 2:3. Heart rate (HR) and oxygen saturation were determined at the ear with a pulse oximeter (Ohmeda Biox). Blood pressure was determined with a cuff placed around the tail (Ohmeda, Finapres). Each time a TOF stimulus was triggered (every 15 s), all variables were requested by the measuring computer from both the pulse oximeter and the blood pressure device. Body temperature was kept at 37-38 C. For monitoring purposes the median nerve of the right arm was stimulated supramaximally near the wrist using needle electrodes. Stimulation was performed with 2 ms square wave pulses in a TOF sequence of 2 Hz with an interval of 15 s delivered by a Grass S88 Stimulator (Grass Medical Instruments, Quincy, MA). The resulting contractions of the thumb muscles were quantified with a force displacement transducer, and recorded on a polygraph.
In the first part of this study, eight experiments were conducted in eight different Rhesus monkeys (body weight 4.2-6.6 kg). After a bolus injection of rocuronium bromide (100 mg kg À1 ), a continuous infusion (infusion rate varied between 285 and 606 mg kg À1 h À1 ) was started to maintain the first twitch contraction of the TOF at approximately 10% of its baseline value. After a steady state block had been maintained for $10 min, the infusion was stopped and the preparation was allowed to recover spontaneously. This process was then repeated, but at the time the infusion was stopped, sugammadex either 0.5 or 1.0 mg kg À1 was given i.v. as a rapid bolus (n=4 for each dose). From the experimental traces TOF ratio recovery times were calculated at 50, 75 and 90% recovery. To verify that these data could be compared in a paired fashion, these experiments were preceded by six placebo experiments, in which the second recovery from 90% block was also spontaneous.
In the second part of the study, two experiments were performed using mivacurium and two using atracurium as neuromuscular blocking agents in four different Rhesus monkeys (body weight 5.2-6.6 kg). After a bolus injection of either mivacurium (100 mg kg À1 ), or atracurium (150 mg kg À1 ), a continuous infusion of mivacurium (infusion rate varied between 403 and 545 mg kg À1 h À1 ) or atracurium (infusion rate varied between 384 and 606 mg kg À1 h À1 ) was started to maintain the first twitch contraction of the TOF at approximately 10% of its base line value. After a steady state block had been maintained for 10 min, the infusion was stopped and the preparation was allowed to recover spontaneously. This process was repeated, but at the time the infusion was stopped, sugammadex 1.0 mg kg À1 was given i.v. as a rapid bolus. Again, from the experimental traces TOF ratio recovery times were calculated at 50, 75 and 90% recovery with and without sugammadex 1.0 mg kg À1 . At the end of the experiments, the animals were allowed to recover from anaesthesia.
Statistics
To evaluate the effect of the reversal agent two methods were used, both taking advantage of the paired character of the data. First recovery times with and without the reversal agent were compared in a simple Student's t-test for paired observations. Also the ratios of recovery times of the TOF_ratio were calculated at 50, 75 and 90% recovery: R 50 =T 50 with/T 50 without, with similar equations for R 75 and R 90 . Then the average ratio of these three variables was calculated: R=(R 50 +R 75 +R 90 )/3. The statistical significance of the reversal effect of the test drug was tested by comparing R 50 , R 75 and R 90 and this averaged ratio R with 1 in a Student t-test for paired observations. As can be concluded from the obtained P-values, using ratios eliminated inter-individual variability in spontaneous recovery times between monkeys. The effect of different doses of the test drug on rocuronium reversal was performed on the same variables with the Student t-test for unpaired data. P-values <0.05 were considered statistically significant. Measurements concerning the recovery times, calculated ratios and relative changes in haemodynamic variables are presented as mean (SD).
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Results
The difference in speed of the recovery of the TOF for sugammadex compared with spontaneous recovery is apparent in Figure 1 . Table 1 presents the data from placebo experiments, in which two spontaneous recoveries were measured in six experiments. From these data and Figure 1C it is clear that the two consecutive spontaneous recoveries for a single Reversal of rocuronium-induced neuromuscular block monkey in a single experiment are very reproducible, allowing evaluation of the effect of a reversal agent in a paired fashion as described.
In the first part of the study, in which rocuronium was the neuromuscular blocking agent, the body temperature of the eight Rhesus monkeys ranged from 37.1 to 37.7 C. Recovery from rocuronium-induced neuromuscular block was significantly faster after treatment with either sugammadex 0.5 mg kg À1 or 1.0 mg kg À1 , compared with spontaneous recovery (Table 2 and Fig. 2) .
In the second part of the study the effect of sugammadex 1.0 mg kg À1 on a constant neuromuscular block of about 90% induced by either mivacurium or atracurium was evaluated. The body temperature of the monkeys ranged from 37.0 to 37.6 C. As determined from the recovery ratios, sugammadex at a dose of 1.0 mg kg À1 had no significant effect on the speed of recovery from mivacurium-or atracurium-induced neuromuscular block, compared with spontaneous recovery (Table 3 and Fig. 2 ). These experiments showed that non-steroidal molecules such as atracurium and mivacurium do not bind to sugammadex. The lack of affinity of sugammadex for these neuromuscular blocking agents has already been clearly demonstrated in other species. 5 7 For ethical reasons, the number of experiments was limited to two animals per non-steroidal drug.
The relative changes in HR and mean arterial pressure (MAP) are presented in Table 4 . Injection of sugammadex had no significant effects on blood pressure or HR (Fig. 1A) . Also in the experiments with either mivacurium or atracurium, sugammadex had no visible effect on HR or arterial blood pressure (Table 4 ).
All animals recovered completely without complication. Signs of residual blockade or re-curarization (up to 1 h after recovery) were not observed in the experiments with sugammadex.
Discussion
Sugammadex (Org 25969), per-6-(2-carboxyethylthio)-per-6-deoxy-g-cyclodextrin sodium, belongs to the family of g-cyclodextrins. This group of oligosaccharides are cylindrical capsules with a lipophilic internal cavity and a hydrophilic exterior. With this lipophilic internal cavity, cyclodextrins are able to encapsulate lipophilic guest molecules such as steroids to form a host-guest inclusion complex. Nuclear magnetic resonance spectroscopy and X-ray crystallography of the host-guest inclusion complex Reversal of rocuronium-induced neuromuscular block between sugammadex and rocuronium showed a tight 1:1 complex with the rocuronium molecule intercalated in the cyclodextrin ring (Fig. 3) . 9 Cyclodextrins are highly water-soluble and do not possess intrinsic biological activity, and therefore it is unlikely that side-effects will occur. 1 3 Sugammadex is excreted rapidly and dose-dependently in the urine of anaesthetized guinea pigs. 10 The present study showed that sugammadex (0.5 and 1.0 mg kg À1 ) caused a rapid and efficient reversal of rocuronium-induced neuromuscular block. In both dose groups the recovery from neuromuscular block was significantly faster than spontaneous recovery. This is most obvious from the recovery ratios that equal unity if there is lack of any effect, and approach to zero in the case of instantaneous 100% recovery. Comparing the recovery ratios for the two different dosages of sugammadex in the rocuronium experiments shows that the difference is close to significant, implying that a dose of 0.5 mg kg À1 does not provide the most efficient reversal. Signs of residual blockade or re-curarization were not seen up to 1 h after recovery. The level of block was selected because in clinical practice reversal of neuromuscular block with neostigmine is ineffective until 10% recovery of the first twitch or the recurrence of the second twitch of the TOF.
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The binding of the rocuronium molecule by sugammadex results in a rapid decrease of the concentration of rocuronium in plasma, in the biophase, and subsequently at the motor endplate. Rocuronium is then less available to block nicotinic receptors in the neuromuscular junction. 12 13 This will promote the liberation of acetylcholine receptors, and in turn muscle activity will reappear.
It should be noted that when interpreting these data that the Rhesus monkey is more sensitive to rocuronium compared with humans (ED 90 in man is $300 mg kg À1 ; in Rhesus monkey ED 90 is $100 mg kg À1 ). Given that sugammadex provides reversal of neuromuscular block by reducing the concentration of free rocuronium, the dose of reversal agent should be increased in humans because the ED 90 for rocuronium in humans is greater than that in the Rhesus monkey. Moreover, there is another obvious difference between Rhesus monkey and man: spontaneous recovery from 90% blockade is much faster in Rhesus monkey than in man.
In vitro studies in the mouse hemi-diaphragm preparation and in vivo studies in guinea pigs showed that sugammadex is almost inactive against neuromuscular block induced by non-steroidal neuromuscular blocking drugs such as succinylcholine, D-tubocurarine, atracurium and mivacurium compared with rocuronium-induced blockade. 5 7 This emphasizes the selectivity of sugammadex in binding rocuronium. The present study confirms and extends these earlier findings by showing that sugammadex at a dose of 1.0 mg kg À1 had no effect on neuromuscular block induced by atracurium or mivacurium. This confirms that the size of the cyclodextrin cavity is too small to accommodate the bulky molecules of mivacurium and atracurium.
Sugammadex has no direct or indirect action on components of cholinergic transmission (cholinesterase, nicotinic receptors or muscarinic receptors), and therefore it is unlikely that muscarinic side-effects will occur. 1 4 In-vivo experiments in cat, guinea pig and Rhesus monkey have confirmed the ability of sugammadex to reverse neuromuscular block induced by rocuronium, without significant cardiovascular side-effects. 6 7 13 In the present experiments significant cardiovascular changes were not observed with sugammadex, indicating that it appears to be free of the cardiovascular effects associated with cholinesterase inhibition, muscarinic antagonism, or both. This can be most easily interpreted from Figure 1A , which is typical of all other experiments, showing that any effect directly related to the injection of the drug is small compared with other variations within the experiment. Moreover, interindividual variation for circulatory variables is substantial. Any observed change in HR or blood pressure was smaller than 10% and very small compared with inter-individual variation. These findings were in agreement with previous studies. 6 13 Cholinesterase inhibitors are not able to reliably reverse the deeper level of neuromuscular block induced by rocuronium. Sugammadex may be able to reverse such a profound neuromuscular block, owing to its unique mechanism of action, but this remains to be determined. Studies on the reversal of profound neuromuscular block are in progress.
In conclusion, in the model sugammadex is a rapidacting reversal agent for neuromuscular block induced by rocuronium, and is without cardiovascular side-effects. This study has shown that the reversal activity of sugammadex is specific to neuromuscular block induced by the steroidal agent rocuronium, and that sugammadex has no effect on neuromuscular block induced by the non-steroidal neuromuscular blocking agents mivacurium and atracurium.
